Comparative Pharmacology
Head-to-head clinical analysis: MINOCIN versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOCIN versus TETRACYN.
MINOCIN vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
100 mg orally or intravenously every 12 hours for 24 hours, then 100 mg every 12 hours; severe infections: 200 mg initially, then 100 mg every 12 hours.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
Terminal elimination half-life is 11–17 hours in patients with normal renal function; prolonged up to 18–69 hours in renal impairment.
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Primarily renal (approximately 70% unchanged) and biliary/fecal (approximately 30%, with enterohepatic recycling).
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic